Navigation Links
PharmAthene Achieves Significant Progress in SparVax™ Anthrax Vaccine Program
Date:9/9/2011

ANNAPOLIS, Md., Sept. 9, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP) announced today that it has achieved significant progress in the development of its second generation anthrax vaccine, SparVax™.  In addition to completing initial technology transfer at the 100 liter scale and demonstrating 36 month stability, the Company announced today that it has now completed a 1,500 liter engineering production run for SparVax™.  As a result, PharmAthene has shown it is able to produce bulk drug substance for SparVax™ at the final commercial scale for the product.

Dr. Thomas Fuerst, Executive Vice President and Chief Scientific Officer, remarked, "PharmAthene has developed a robust manufacturing process for SparVax™ with the capability to produce more than 200 million rPA vaccine equivalent doses of bulk drug substance at the 50 mcg dose range on an annual basis.  The use of recombinant vaccine technology employing modern, industrial biotechnology manufacturing processes provides the flexibility to rapidly scale-up production in the event of a national emergency, which should enable a much more refined and cost-effective vaccine for the U.S. government and its citizens."

"As we remember and honor those who tragically lost their lives on September 11, 2001, we must not forget that it was also 10 years ago that our nation was introduced to the specter of biological terrorism in the form of the anthrax letter attacks.  Since those tragic events, our government has dedicated unprecedented resources to ensuring our nation's preparedness against future bioterrorism events," remarked Eric I. Richman, President and Chief Executive Officer for PharmAthene.  

"Recently, the Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services (HHS) released The Public Health
'/>"/>

SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Lord Lewis Moonie to Serve as Special UK Government Advisor to PharmAthene
2. PharmAthene Reports Second Quarter 2008 Financial and Operational Results
3. PharmAthene Response to DHHS Request for Proposals for Recombinant Protective Antigen Anthrax Vaccine Deemed Technically Acceptable and Within Competitive Range for Procurement Consideration
4. PharmAthene to Present at the UBS Global Life Sciences Conference on Thursday September 25, 2008
5. PharmAthene to Present Data for Protexia(R) and Valortim(R) at HHS PHEMCE Stakeholders Workshop 2008
6. PharmAthene Awarded NIAID Contract For Up to $83.9 Million For Third Generation rPA Anthrax Vaccine Program
7. PharmAthene and Panacea Biotec Ltd. Establish Strategic Alliance in Biodefense and Emerging Infectious Diseases
8. Medarex And PharmAthene Announce New Therapeutic Data for Anthrax Anti-Toxin, Valortim(R)
9. PharmAthene to Present on Wednesday, November 12th at the 10th Annual Rodman & Renshaw Healthcare Conference
10. PharmAthene to Host Third Quarter 2008 Conference Call and Webcast on Thursday, November 13, 2008
11. Pharmathene Reports Third Quarter 2008 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Yan, Distinguished Professor of Engineering at the University ... to solve problems in energy engineering, environmental sustainability ... on zeolites, porous rock with a well-defined, crystalline ... is so precisely decided that zeolites can separate ... of an angstrom (one-tenth of a nanometer), making ...
(Date:7/24/2014)... 24, 2014 Your cell phone ... modeling lithium-ion battery storage capacity. , New research ... theoretical model created at Lawrence Livermore National ... predicts how carbon components will perform as electrodes. ... the urgent need for higher-performance batteries. Several key ...
(Date:7/24/2014)... 24, 2014 2014 Deep Research ... is a professional and in-depth research report on ... Sulphate basic information, including its definition, classification, ... This research covers the international market analysis, including ... analysis covering macroeconomic environment & economic situation analysis, ...
(Date:7/24/2014)... The first part of the session on “Best ... Studies” will cover comprehensive clinical support in early phase ... R&D costs and declining industry success in getting products ... collected in early Phase I/IIa study data to make ... development. , Next, the presenters will examine steps to ...
Breaking Biology Technology:University of Delaware researcher describes new approach for creating organic zeolites 2Getting More Life out of Lithium-ion Batteries 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 2Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 3Potassium Sulphate Market & SHMP Industry 2014 (Global, China) Analysis Now Available at DeepResearchReports.com 4Best Practices for Optimizing Dose Escalation in First in Human Studies, New Webinar August 6th Hosted by Xtalks 2
... Jan. 29 CuraGen Corporation (Nasdaq: CRGN ), ... and calendar year of 2008 and provided milestone and ... three month period ended December 31, 2008, CuraGen utilized ... fourth quarter with $88 million of cash and investments. ...
... development and production, today announced the appointment of David Pyrce as its ... ... Los Angeles (PRWEB) January 29, 2009 -- Nexsun Corp, a leader in ... David Pyrce as its Chief Executive Officer and member of the Board ...
... (Nasdaq: SGMO ) today announced that the ... financial results on Wednesday, February 4, 2009, after the ... a conference call at 5:00 p.m. ET, which will ... During the conference call, the company will review the ...
Cached Biology Technology:CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009 2CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009 3CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009 4CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009 5CuraGen Reports Fourth Quarter 2008 Financial Results; Provides Milestone and Financial Guidance for First Half of 2009 6Nexsun Corp Names Industry Executive David Pyrce as Chief Executive Officer 2Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast 2Sangamo BioSciences Announces Fourth Quarter and Year-End 2008 Conference Call and Webcast 3
(Date:7/25/2014)... consume the healthcare community and remain priority ... To address the worldwide crisis of obesity ... global leaders in diabetes, epidemiology and public ... and development of diverse intervention programs in ... This book on "Global Health Perspectives in ...
(Date:7/25/2014)... University of Adelaide has opened the way for the development ... , In Australia, annual barley production is second only to ... one of the most important diseases of barley. , Senior ... composition of special growths on the cell walls of barley ... leaf. , The research, by the ARC Centre of Excellence ...
(Date:7/25/2014)... pleiotropic factor characterized by the existence of numerous ... confer to the protein deeply different characteristics. NRG1 ... occurring during development and the different phases occurring ... axon regrowth, remyelination and target reinnervation, Researchers at ... the soluble NRG1 upregulation observed in Schwann cells ...
Breaking Biology News(10 mins):What constitutes an effective response to the global 'diabesity' tsunami? 2New hope for powdery mildew resistant barley 2
... contamination of drinking water does not have a ... of Wisconsin-Madison researchers on arsenic-tainted wells shows that ... the contamination. Naturally occurring arsenic in rocks ... where it poses no threat to groundwater, explains ...
... maps that allow conservationists to estimate the distribution of ... threatened species and those with specific habitats, according to ... Conservation Biology. Our study found that species ranges ... trend is particularly pronounced for birds that are threatened, ...
... dinosaur from the Early Jurassic has been discovered in ... Glacialisaurus hammeri and lived about 190 million years ago. ... is based on partial foot, leg and ankle bones ... Antarctica at an elevation of more than 13,000 feet. ...
Cached Biology News:Arsenic contamination lacks one-size-fits-all remedy 2Arsenic contamination lacks one-size-fits-all remedy 3Threatened birds may be rarer than geographic range maps suggest 2Threatened birds may be rarer than geographic range maps suggest 3Massive dinosaur discovered in Antarctica sheds light on life, distribution of sauropodomorphs 2
For the quantitative determination of cyclic AMP (cAMP) concentrations in cell culture supernates, serum, plasma, saliva, urine and cell lysates....
FRACTALKINE [Human] (Recombinant)...
... head automatically rises at the end of determination; triple-point calibration verification; refrigerator eliminates need for pumps and bath ... * ... ... ...
... The Luminex® 200 System with ... for developing single and multi-analyte assays ... contains the new, powerful user friendly ... user can design specific templates for ...
Biology Products: